Koide Laboratory - Synthetic Protein Science

We aim to advance the knowledge of how proteins and protein interaction networks work by “synthetic” approaches, i.e. designing and making proteins with novel function.  This "learning by building" approach critically tests our understanding of principles that govern protein structure, function and evolution, and it challenges our creativity.

We are now capable of producing highly functional synthetic proteins within weeks.  Structural and functional analysis of synthetic proteins not only critically evaluates the effectiveness of our design strategies but also provides broader insights into the molecular mechanism and evolution of protein form and function.  Knowledge gained from the synthetic approach complements and very often significantly expands the view from classical studies of natural proteins.

Synthetic proteins serve as novel and transformative tools for basic and translational research in medicine and beyond.  We are particularly interested in applying our capability to:

  • Development of biologics therapeutics (engineered proteins and antibodies)
  • Signal transduction and cancer biology
  • Structural biology
  • Synthetic biology

Why synthetic protein science?


Postdoctoral and Research Technologist positions available in developing biologics therapeutics - Contact Shohei Koide

July 2023 - Our paer on the development of KRAS(G12D)-selective monobodies and the identification of new pocket conformation of KRAS(G12D) using the monobodies is published in PNAS (open access).

May 2023 - Our review paper on the use of phage and other display technologies for monobody development is published in Cold Spring Harbor Protocols.

February 2023 - Our paper on monobodies selective to the phosphatase domain of SHP2 and their utility as mechanistic tools is published in J Mol Biol.

January 2023 - The print version of our Cancer Discovery paper is out, accompanied with a commentary by Adrianne Cox, Jenny Ting and Channing Der, and the journal cover illustration for the January issue. Also highlighed by Science.

December 2022 - Shohei was elected as a Fellow of the National Academy of Inventors.

November 2022 - Our collaborative paper with the O'Bryan group on the nature of RAS self-association is published in JBC.

October 2022 - Our paper on an approch that unifies small molecule targeted therapy and immune therapy is published in Cancer Discovery. It is highlighted by the National Cancer Institute and in NYU press release.

October 2022- Our paper on a pan-RAS monobody is published in PNAS.

October 2022 - Our paper on the discovery of a human protein that protects Crohn's disease susceptability, a collaboration with Prof. Ken Cadwell's group, is publshed in Nature.

April 2022 - Our review on engineering exquisite specificity is published in Methods Mol Biol.

March 2022 - A multi-disciplinary collaboration among five labs at NYU School of Medicine and NYU Chemistry reveals a new way to inhibit MRSA. A new paper published in Nature Chemical Biology. Highlighed in News & Views and in NYU press release.

March 2022 - Our paper with Prof. Randy Stockbridge on cool protein engineering to repurpose a monobody crystallization chaperone for determing the long-sought-after crystal structures of EmrE with multiple ligands is published in Elife.

February 2022 - Our paper establishing the nucleotide-free RAS as a druggable target is published in Cell Reports. Our monobody technology played the crucial role in this discovery (again).

December 2021 - Our paper on the development of cytotoxic antibodies targeting CD99 for leukemia therapy is published in J Mol Biol.

September 2021 - A comprehensive review by Padma and Kevin on target validation with monobodies is published in RSC Med Chem.

June 2021 - Our paper with Prof. S. Burden's group on antibody rescue of congenital myasthenia is published in Nature. The paper was highlighted in Nature Rev Drug Discovery.